List view / Grid view
Antibody-drug conjugates (ADCs) are designed to be highly-targeted therapies with the potential to maximise the potency of a treatment while reducing unwanted side effects on healthy tissues. Some 20 years after the first ADC product approval, Dominik Schumacher and Jonas Helma-Smets of Tubulis GmbH discuss how improved and optimised technologies…
Market research suggests the global formulation development outsourcing market will significantly expand in coming years, owing to disease burden and R&D expenditure.
New research suggests microparticles able to release their payloads at different times could form the basis of self-boosting vaccine courses that would require just a single injection.
A new study demonstrates the design and potential of adding artificial components to bacteria to enable tumour targeted drug release and immune activation.
Researchers have developed a rapid, label-free process analytical technology, called the anomaly detection model, to monitor microbial contamination in cell cultures in near-real-time.
The UK Government has announced the launch of the Innovative Medicines Fund to bring cutting-edge treatment more quickly to NHS patients.
Driven by oncology drug demand, the highly potent active pharmaceutical ingredients (HPAPIs) market is anticipated to grow by $7bn in three years.
A unique partnership, the Access to Oncology Medicines (ATOM) Coalition, has been established to ensure sustainable access to cancer medicines in low- and lower middle-income countries (LLMICs) in the long-term.
A new study published in the Journal of Controlled Release reports some intriguing developments in the tumour-targeting delivery of nanomedicines.
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz-300x278.jpg)
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz.jpg)
The new €275 million facility will be used to manufacture medicinal products for cancer and cardiovascular diseases and is scheduled to be ready for operation in 2024.
According to a new report, biologics are forecast to have $120 billion greater sales than small molecules by 2027.
Targeting medicines against the genetic and molecular drivers of lung, breast and other tumours has helped transform cancer care for many patients, yet precision medicine for complex chronic diseases has lagged behind. Maria Orr, Adam Platt and Ben Challis, from BioPharmaceuticals R&D at AstraZeneca, explain why this is changing for…
Most therapeutic approaches in immuno-oncology focus on targeting the adaptive immune system; innate immunity has only recently gathered momentum. One of the most potent receptors for activating innate immune cells such as natural killer cells and macrophages is CD16A. Addressing this target mimics the body’s natural defense against potential threats,…
Features in this in-depth focus highlight developments in the MRI contrast agent space, explore the development of precision medicine for chronic diseases and explain why immunotherapies should engage the innate immune system in the fight against cancer.
A team of scientists has developed a spherical nucleic acid (SNA) vaccine, which has demonstrated high efficacy as a COVID-19 therapy, as well as an anti-cancer treatment in rodents.
